TheraRadar

Pharma Intelligence, Simplified

← Back
Data updated: Mar 10, 2026

MANNKIND

MetabolicInfectious DiseaseRespiratory
Biotech

MANNKIND is a biotechnology company focused on Metabolic, Infectious Disease, Respiratory. Key products include AFREZZA.

2014
Since
1
Drugs
-
Trials
1
Approved (2yr)

Key Drugs

AFREZZA
insulin recombinant human
Metabolic
1 indications · 2014

Recent Activity

AFREZZA 2026-01-23
Efficacy
SEC Filings Pro
Loading...

Therapeutic Focus

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Metabolic 73%
1 drugs Phase 3: 1 Phase 2: 2 Phase 1: 5
Infectious Disease 15%
0 drugs Phase 3: 1
Respiratory 8%
0 drugs Phase 1: 2
Cardiovascular 4%
0 drugs Phase 1: 1

Pipeline Strength Pro

Loading...

Competitors Pro

Merck big-pharma
Infectious Disease, Cardiovascular, Metabolic
Johnson & Johnson big-pharma
Infectious Disease, Cardiovascular, Metabolic
Sanofi big-pharma
Metabolic, Infectious Disease, Respiratory
B BRAUN specialty
Infectious Disease, Metabolic, Cardiovascular
AstraZeneca big-pharma
Respiratory, Cardiovascular, Metabolic